Amgen Inc. (NASDAQ:AMGN) Shares Sold by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 25.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,480 shares of the medical research company’s stock after selling 5,561 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Amgen were worth $4,295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the third quarter valued at about $29,000. Matrix Trust Co purchased a new position in Amgen during the third quarter worth about $36,000. Heck Capital Advisors LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $285.42 on Monday. The firm has a fifty day moving average price of $271.06 and a 200 day moving average price of $304.33. The stock has a market cap of $153.42 billion, a PE ratio of 36.55, a price-to-earnings-growth ratio of 2.85 and a beta of 0.56. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.34%. Amgen’s dividend payout ratio is 121.90%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Bank of America reaffirmed an “underperform” rating and set a $256.00 price objective on shares of Amgen in a research report on Tuesday, December 10th. Barclays raised their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.